Nordson Deep Value Investment Research

Cost structure. Nordson's gross margin has stayed around 54%-55% for a long time, materially above that of ordinary traditional machinery manufacturers. This shows that its value comes from process know-how, reliability, validation, application engineering, and parts/consumables rather than simple manufacturing. The company's 2020-2025 IR summary gives an average gross margin of about 55% and an average EBITDA margin of about 30%, broadly consistent with the annual report presentation.

Dependence on a few customers, suppliers, channels, policies, or key people. Customer concentration is low. Raw materials and components are "generally available from multiple sources," and suppliers are selected competitively based on cost, quality, and service. The larger dependencies are global industrial capital spending, the electronics cycle, the pace of medical customer project validation, and international trade and tariffs, rather than any single customer or supplier. In addition, 67% of 2025 revenue came from outside the United States, making foreign exchange and cross-border trade conditions more important.

Whether the accounting and business model are simple enough. Revenue recognition is mainly based on short-term fixed-price contracts and is "primarily recognized at a point in time," while revenue recognized over time accounts for less than 10% of total revenue. This is a relatively direct and understandable industrial accounting model. Complexity comes more from acquisitions, amortization of intangibles, segment adjustments, and global operations than from revenue recognition itself.

If the stock market closed for five years, would I be willing to hold it? If my purchase price were reasonable enough, I would be willing to hold this business for the long term. If I bought at too high a valuation, I would not ignore price simply because the business is excellent. It belongs in the category of "willing to hold, but only at the right price."

Business understandability score: 4/5. The underlying business logic is clear, but the specific product lines and acquisition puzzle are numerous, making it more complex than a single industrial consumables company.

Industry and competitive structure. This is a combination of multiple niche precision industrial and medical manufacturing links rather than a single industry: mature industrial automation, structurally growing medical intervention/fluid components, and more volatile electronics/semiconductor-related testing and inspection. Nordson itself listed Graco, IDEX, AMETEK, Entegris, MKS, Teleflex, and others in the peer reference group in its 2025 proxy statement, which shows that external observers also view it as a composite platform spanning industrial, medical, and electronics niches.

Industry demand and attractiveness. Long-term demand is not poor. Packaging, industrial dispensing and coating, medical fluid components, semiconductor packaging, and inspection are not short-lived needs. But the cycle is not smooth: electronics, polymer processing, agriculture, and industrial coating all have cyclicality. Nordson itself also acknowledges in its risk factors that markets such as electronics, polymer processing, agriculture, and metal surface treatment are historically cyclical.

Whether the industry is vulnerable to technology or regulatory disruption. The medical and electronics segments face technological iteration and validation requirements. These are both risks and entry barriers. The company lists risks related to data privacy, AI, intellectual property, trade policy, and tariffs. My judgment is: overnight disruption is unlikely, while product iteration and process substitution risks are real.

Company position and pricing power. Nordson does not use sweeping language such as "number one market share" across all segments, but it repeatedly emphasizes differentiated technology, application engineering, and global service. In 2022, the company was able to use price increases to offset inflation, proving some pricing power. But the 2025 annual report also acknowledges that passing cost increases to customers has historically involved delays, which means this pricing power is not unconditional.

Industry attractiveness score: 3.5/5. This is a combination of good niches, not a "golden industry with no cyclicality." Over the long term, Nordson looks more like a company that operates excellently in ordinary industries while occupying several important process nodes.

Moat and Management

Below I break down the moat dimension by dimension.

Is the moat widening, stable, or narrowing? My judgment: overall stable, locally widening. In medical and precision electronics platforms, the moat may be widening due to validation, customer relationships, and embedding in key processes. But industrial cyclicality and acquisition integration make the rate of moat widening at the group level less intuitive than at some top-tier consumer brands.

How long and how much capital would competitors need to replicate it? Replicating a single mechanical product is not hard. Replicating Nordson's combination of a "global direct sales and service network + multi-niche product library + process know-how + medical/electronics validation relationships + acquisition platform capability" would require many years and sustained capital. Especially in medical intervention and electronics inspection, capital alone is not enough; competitors also need long-term customer validation and accumulated application experience.

Can it raise prices in an inflationary environment? Yes, but it cannot immediately pass through everything whenever it wants. In 2022, the company explicitly said results were "inclusive of pricing to offset inflation." But the 2025 risk factors also noted that passing raw material price increases to customers has historically involved delays. In other words, Nordson has pricing power, but not absolute monopoly-style pricing power.

Can it remain profitable in an economic downturn? Yes, though margins will fluctuate. In 2020, Nordson still generated revenue of $2.121 billion, operating profit of $350 million, and net income of $250 million, showing that the business model has earnings resilience through downturns.

Were past high margins structural advantage or cyclical benefit? My judgment leans toward structural advantage as the primary driver, with cycle as a secondary factor. Long-term gross margins around 55% and consistently high cash conversion do not look like a pure cyclical windfall. But the recovery in ATS and electronics-related demand in the first half of 2026 did amplify margin performance.

Moat strength score: 4/5. This is a process-embedded, application-engineering, service-driven industrial moat, different from a Coca-Cola-style brand moat or a Microsoft-style network-effect moat.

Is management trustworthy? There are many positive signals: CEO Sundaram Nagarajan has served as CEO since 2019; the board has an independent chair; the company has clear executive stock ownership requirements, clawback provisions, anti-hedging/anti-pledging policies, double-trigger change-in-control provisions, and the latest Say-on-Pay vote received 97.3% support.

But alignment is not perfect. The 2026 proxy statement shows the CEO owned about 190,193 shares, while management and directors together owned about 470,304 shares, still below 1% in aggregate. This means alignment between management and shareholders relies more on compensation mechanisms than on very high personal ownership. Value investors should not ignore this point.

Is capital allocation rational? I would rate it "above average" rather than "excellent." On one hand, the company has raised its annual dividend for 62 consecutive years. It continued buybacks from 2023 to 2025, repurchasing 1.4 million shares in 2025 for about $299.6 million, at an average price of about $214/share, clearly below the current price range, so this cannot fairly be called buybacks merely to polish EPS. On the other hand, the company has made acquisitions such as ARAG, Atrion, and CyberOptics in recent years. These did strengthen the platform, but also pushed up goodwill and debt. Whether all of these acquisitions create value still needs a longer observation period through ROIC and organic growth.

Management and capital allocation score: 3.5/5. I am willing to give a positive assessment, though not a perfect score. The reason is simple: governance is good and buybacks have not been reckless, while M&A is too important in Nordson's model and is inherently the area where management teams most easily overestimate their own ability.

Financial Quality and Owner Earnings

The table below uses the company's 2022, 2023, and 2025 10-K filings and fiscal Q2 2026 earnings release. Margins, FCF, leverage, ROE/ROIC, and other figures are observational calculations I made from disclosed numbers. ROE/ROIC use a simplified approach for cross-sectional comparison, with more weight on trend than decimal-level precision.

Revenue and profit trend. Revenue grew from $2.362 billion in 2021 to $2.792 billion in 2025, a nominal CAGR of roughly 4%. If extended to the first half of fiscal 2026, growth continued to accelerate. Margins have not collapsed over the long term and instead showed solid resilience despite acquisition integration and electronics-cycle disruption. More importantly, FCF has been no lower than net income in most years, and in the last two years it has been meaningfully higher than net income.

Are profits real cash profits or accounting profits? They lean toward real cash profits. There are three strong pieces of evidence: First, operating cash flow has covered net income over the long term. Second, capital intensity is low: capital expenditures in 2025 were only $58.06 million, about 2.1% of revenue. Third, revenue is mainly recognized at a point in time, with less than 10% recognized over time, leaving relatively limited room for accounting manipulation. The real reason GAAP profit and cash flow differ meaningfully is the large amortization of intangible assets created by acquisitions, rather than poor cash quality.

Does growth depend on heavy capital investment? Organic growth is light on capital expenditures. The real capital consumer is M&A. Nordson's spending on plant and equipment has remained low, but transactions such as ARAG in 2023 and Atrion in 2024 increased the size of the balance sheet, interest costs, and goodwill. In other words, this company is "capital-light operationally and moderately dependent on external growth strategically."

Is the balance sheet sound? It is fair to call it sound, but it is no longer as light as it used to be. Total debt was about $2.0 billion at the end of 2025 and about $1.886 billion at the end of April 2026. Based on my rough TTM EBITDA calculation, net debt/EBITDA is around 2x, still acceptable. The company's credit agreements also require leverage and interest coverage constraints, and the covenant structure disclosed in 2025 still had room.

But there is one important negative point: the asset cushion is weak. At the end of 2025, shareholders' equity was about $3.044 billion, while goodwill was $3.305 billion and net intangible assets were $682 million. On a simple basis, tangible net assets were negative. This means Nordson's investment case is almost entirely built on "continuing earning power" rather than "asset liquidation value." Conservative investors must take this seriously.

Any abnormal working-capital signals? In 2025, receivables fell from $595 million to $588 million, and inventory fell from $477 million to $445 million, showing good operating discipline. By the end of April 2026, receivables and inventory had seasonally risen again to $607 million and $468 million, while payables and accrued liabilities were broadly stable. This looks more like normal order and delivery rhythm than aggressive credit extension or passive inventory buildup.

Accounting risk and signs of earnings manipulation. I do not see obvious signs of financial fraud or aggressive recognition, but two points require ongoing attention: First, acquisition accounting creates large amounts of goodwill, customer relationship amortization, and "adjusted profit" metrics, which can make investors overlook the real cost of capital. Second, the company frequently makes non-GAAP adjustments, so understanding the business requires returning to cash flow and returns on capital. The good news is that Nordson has at least not disappointed on cash-flow realization.

Conservative Owner Earnings estimate. I use two approaches: First, the broad approach, directly treating TTM FCF as Owner Earnings, about $714 million. Second, the conservative approach, starting from TTM operating cash flow of about $762 million, subtracting all capital expenditures of about $48 million, and then removing about $45 million of TTM working-capital release benefits as non-sustainable. Conservative Owner Earnings are therefore about $668 million. This equals about $11.9/share, and at a share price of about $287, implies about 24x conservative Owner Earnings. Using the broad approach, it is about 22x.

Owner Earnings conclusion. Nordson's true distributable cash capacity has been above, or at least close to, net income over the long term, which is a major positive. But the current market has clearly already paid a meaningful price for this quality.

Valuation and Margin of Safety

Current valuation snapshot. As of the 2026-05-29 closing price I found, NDSN was about $287.33. Based on the TTM calculations above, the valuation was roughly: TTM EPS of about $9.36, equal to 30.7x P/E; TTM FCF of about $714 million, equal to about 22x P/FCF; conservative Owner Earnings of about $668 million, equal to about 24x P/OE; and an annualized dividend of about $3.28/share, for a dividend yield of about 1.1%.

Method 1: Owner Earnings discounting. I use conservative Owner Earnings of $668 million as the starting point and model three scenarios with a conservative discounting mindset. This is an inference, not a fact.

These ranges reflect this idea: as long as Nordson continues to maintain high cash conversion and operates its medical, electronics, and industrial niche platforms well, it does not lack long-term value. But under conservative requirements, the current share price does not fully account for the risks of growth misses, integration misses, or valuation mean reversion.

Method 2: relative valuation. On current numbers, Nordson sits roughly in the high-end valuation band for high-quality industrial/precision manufacturing assets. It is not cheap. More importantly, comparing it with the broader market and the risk-free rate does not lead to an easy conclusion: FactSet gave the S&P 500 a forward 12-month P/E of about 21.0x on 2026-05-08, while the U.S. Treasury's 10-year yield on 2026-05-29 was about 4.27%. By comparison, Nordson's current conservative Owner Earnings yield is only about 4.2%, and its TTM FCF yield is about 4.5%, leaving conservative investors little valuation redundancy.

From an operating-quality perspective, peer Graco generated 2025 revenue of about $2.237 billion, net income of about $522 million, operating cash flow of about $684 million, and year-end cash of about $624 million, with a lighter balance sheet. IDEX generated 2025 revenue of about $3.458 billion, free cash flow of about $617 million, and total borrowings of about $1.830 billion. ITW generated 2025 revenue of about $16.044 billion, free cash flow of about $2.707 billion, and total debt of about $8.969 billion. This comparison at least shows that Nordson is high quality, but it is not in a position where peers are obviously worse while Nordson is obviously cheaper.

Method 3: asset or liquidation value. This company is not suitable for book-value liquidation analysis as the main valuation method. At the end of 2025, cash was about $108 million, total debt was about $2.0 billion, goodwill was about $3.305 billion, net intangible assets were about $682 million, and book shareholders' equity was about $3.044 billion. This means Nordson's tangible asset protection is not strong. If you buy this company, you are essentially buying its earning power over the coming decades, not a package of assets below liquidation value.

Intrinsic value range and price bands. Based on the three methods above, my conclusion is as follows:

At a share price of about $287, Nordson roughly falls from the lower end to the middle of my fair value range. This means: it is not clearly overvalued, but for new capital with a balanced but conservative mandate, it also does not offer enough margin of safety.

Margin of safety judgment. The three most fragile valuation assumptions are: First, Owner Earnings can keep growing at a 6%-8% rate over the medium to long term. Second, acquired assets such as ARAG and Atrion can ultimately restore ROIC to a better level. Third, the market remains willing to award a valuation premium to a high-quality industrial platform. If any one of these fails, it becomes harder for Nordson to deliver excellent returns from the current price. My clear judgment is: the current margin of safety is insufficient.

Comparison with indexes, risk-free yield, and alternatives. For a long-term investor who can choose broad market indexes, I do not think buying Nordson now is clearly superior to buying the index. The issue is price: the company's high quality is already partly reflected in the valuation. Compared with the 10-year Treasury yield of 4.27%, Nordson's long-term expected return is of course higher, but for a conservative investor this excess return is not large enough to ignore price risk. My judgment: it deserves a place on a high-quality watchlist, but at the current price it does not deserve too much capital.

Risks, Checklist, and Final Judgment

The most important risks. First, M&A risk. Nordson's growth strategy clearly includes substantial acquisitions, and several large recent deals have materially raised goodwill and debt. If integration, cross-selling, or margin realization disappoints, ROIC could remain depressed for a long time. Second, cyclical risk. Electronics, semiconductor-related testing and inspection, polymer processing, agriculture, and industrial coating are not fully cycle-proof. Third, valuation risk. If the market re-rates Nordson from a "high-quality compounding platform" to a "mid-speed growth, acquisition-heavy industrial company," multiple compression would hurt. Fourth, balance sheet quality risk. Tangible net assets are weak, and asset-based protection is limited. Fifth, international business risk. With 67% international revenue, foreign exchange, tariffs, and global trade policy all affect profit realization.

The strongest bear case. The strongest bear argument is simple: Nordson is a very good industrial platform, but perhaps not as scarce as investors imagine, while the current share price already assumes continued high-quality growth. If the following happen over the next few years, investors buying at today's price could suffer: First, the electronics/semiconductor chain rolls over and ATS growth slows. Second, Atrion and ARAG synergies disappoint and ROIC improvement is limited. Third, the market becomes unwilling to pay around 30x earnings. In an extreme case, if Owner Earnings fall back to $450-500 million and the market assigns only a 15-18x cash earnings multiple, the corresponding share price could return to the $120-180 range, implying a roughly 35%-60% risk of permanent capital loss. This is the scenario I think deserves the most respect.

What facts would overturn this investment judgment? If the following facts emerge, I would admit that the original judgment needs to be rewritten: First, FCF remains materially below net income for several consecutive years and cash conversion deteriorates. Second, net debt/EBITDA stays above 2.5x for a long time with no downward trend. Third, organic growth in the medical and electronics platforms remains below the industry after acquisitions, and ROIC continues to decline. Fourth, management clearly shifts from "pursuing per-share intrinsic value growth" to "pursuing scale." Fifth, key businesses suffer technology substitution, loss of customer validation, or weakened pricing power.

Investment Checklist.

Final rating. Watch

One-sentence investment thesis. Nordson is a high-quality, strong-cash-flow precision industrial platform with a process-embedded moat, but near the current price of about $287, the price is close to fair value rather than clearly undervalued.

Core bull points. The business is diversified across multiple niche markets with long-term demand, and customer concentration is low. Gross margin has stayed around 55% for a long time, showing that its value comes from process and application expertise rather than simple manufacturing. Free cash flow has long been close to or above net income, indicating high cash earnings quality. The global direct sales and service network, aftermarket parts and consumables, customer validation, and switching friction form a stable moat. Governance and the shareholder return culture are generally healthy, and 62 years of consecutive annual dividend increases is rare.

Core bear points. The current valuation is not cheap, and the margin of safety is not clear. Dependence on acquisitions is relatively high, and goodwill and intangible assets are heavy. ROIC has fallen below the historical asset-light period due to recent acquisitions, and whether it can recover remains to be proven. Electronics/semiconductor and some industrial end markets have cyclical volatility. Tangible asset protection is weak, making this unsuitable as a "liquidation value floor" investment.

Key assumptions. Owner Earnings can compound at 5%-8% over the next ten years. Medical and Fluid Solutions and ATS continue to maintain high gross margins and strong customer stickiness. Major acquisitions do not materially damage the balance sheet or ROIC. Valuation may eventually decline, but it does not fall back to the low range of ordinary capital goods companies.

Fair buy price. I would be more willing to establish or add to a position in the $220-250 range. That range sits between my conservative and base values and would provide a more acceptable margin of safety.

Target holding period. More than 10 years. This company is not suited to making money from quarterly volatility. It is better suited to earning through long-cycle cash flow and reinvestment capability.

Expected annualized return. This section is an inference, not a fact. Based on the current share price of about $287: Conservative scenario: 5%-7%; Base scenario: 8%-10%; Bullish scenario: 11%-13%. These returns are not poor, but for conservative capital they are also not high enough to ignore price.

Maximum downside risk. If acquisition synergies disappoint, the electronics cycle turns down, and valuation multiples compress toward the range of more ordinary industrial companies, a pullback toward $120-180 is not unimaginable, corresponding to a possible 35%-60% permanent capital loss.

Indicators to keep tracking. Organic growth by segment, especially ATS and MFS. Free cash flow conversion. Net debt/EBITDA. Operating margin and segment EBITDA. ROIC recovery after acquisitions. Inventory, receivables, and payables turnover trends. Resilience of aftermarket parts/consumables and service revenue. New product and customer validation progress in the medical business. Electronics inspection business and semiconductor packaging demand. Buyback prices and acquisition discipline.

Signals that would trigger reassessment. FCF is weaker than net income for two to three consecutive reporting periods. Leverage rises materially again. Segment organic growth underperforms end markets for a long time. Management starts emphasizing scale, adjusted profit, and acquisition stories more than per-share cash flow and returns on capital. Technology substitution causes gross margin or customer retention in key product lines to deteriorate.

Final recommendation. Calmly put, Nordson is worth studying, worth following for the long term, and worth considering as a large position at a better price. But under this conservative framework, it is not yet cheap enough for me to feel sufficiently comfortable about permanent capital loss. If you already hold it, I would lean toward holding and continuing to track it. If you are preparing to buy a new position, I would prefer to wait for a wider margin of safety. The conclusion reflects purchase discipline, not doubt about the company's quality.

Open questions and limitations. The company does not disclose exact recurring revenue, aftermarket parts/consumables revenue, or maintenance capital expenditure percentages, so Owner Earnings can only be conservatively estimated rather than precisely reconstructed. The peer relative valuation section in this research focuses more on operating quality and directional comparison, and does not fully expand every peer's real-time market multiples. Therefore, the valuation conclusion in this report should rely mainly on Nordson's own discounted cash flow and margin of safety.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.